Ratings Shield Therapeutics plc

Equities

STX

GB00BYV81293

Delayed London S.E. Other stock markets 08:30:53 2024-05-14 am EDT			5-day change	1st Jan Change
1.98 ^GBX	+4.21%		+25.71%	-70.45%

May. 10	Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 30	EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	AN

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
With regards to fundamentals, the enterprise value to sales ratio is at 1.08 for the current period. Therefore, the company is undervalued.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SHIELD THERAPEUTICS PLC	-70.45%	18.65M	-
VERTEX PHARMACEUTICALS INCORPORATED	+5.02%	111B	B+
REGENERON PHARMACEUTICALS, INC.	+10.90%	105B	B+
BIONTECH SE	-12.35%	22.34B	B+
ARGENX SE	-3.26%	21.93B	B
GENMAB A/S	-5.75%	18.59B	A-
WUXI APPTEC CO., LTD.	-36.52%	18.12B	A-
BEIGENE, LTD.	-9.51%	16.96B	B
NEUROCRINE BIOSCIENCES, INC.	+3.64%	13.7B	C+
SAREPTA THERAPEUTICS, INC.	+37.05%	12.45B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes